Literature DB >> 23928677

Clinical course of vitreomacular adhesion managed by initial observation.

Vishak J John1, Harry W Flynn, William E Smiddy, Adam Carver, Robert Leonard, Homayoun Tabandeh, David S Boyer.   

Abstract

PURPOSE: The purpose of the study was to investigate the clinical course of patients with idiopathic vitreomacular adhesion (VMA).
METHODS: A noncomparative case series of patients who had clinical symptoms and spectral-domain optical coherence tomography findings consistent with VMA. The VMA was graded based on the optical coherence tomography findings at initial and follow-up examinations. Grade 1 was incomplete cortical vitreous separation with attachment at the fovea, Grade 2 was the Grade 1 findings and any intraretinal cysts or clefts, and Grade 3 was the Grade 2 findings and the presence of subretinal fluid.
RESULTS: One hundred and six eyes of 81 patients were identified as having VMA by spectral-domain optical coherence tomography at 3 retina clinics. The mean age was 73 years and the mean time of follow-up was 23 months. Forty-three eyes (41%) had Grade 1 VMA, 56 eyes (52%) had Grade 2 VMA, and 7 eyes (7%) had Grade 3 VMA. By the last follow-up, spontaneous release of VMA occurred in 34 eyes (32%), and pars plana vitrectomy was performed in 5 eyes (4.7%). Mean best-corrected visual acuity was 0.269 logarithm of the minimum angle of resolution or 20/37 at baseline (range, 20/20-20/200) and logarithm of the minimum angle of resolution 0.251 or 20/35 at the last examination (range, 20/20-20/400).
CONCLUSION: In this selected patient cohort with mild symptoms, the clinical course of patients with VMA managed by initial observation was generally favorable.

Entities:  

Mesh:

Year:  2014        PMID: 23928677     DOI: 10.1097/IAE.0b013e3182a15f8b

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  21 in total

1.  The design and validation of an optical coherence tomography-based classification system for focal vitreomacular traction.

Authors:  D H W Steel; L Downey; K Greiner; H Heimann; T L Jackson; Z Koshy; D A H Laidlaw; L Wickham; Y Yang
Journal:  Eye (Lond)       Date:  2016-01-15       Impact factor: 3.775

2.  Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?

Authors:  Christoph Paul; P Krug; H H Müller; J Wachtlin; S Mennel; S Müller; S Schmitz-Valckenberg; T Bertelmann; R G Schumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-28       Impact factor: 3.117

3.  Evolution of vitreomacular adhesion to acute vitreofoveal separation with special emphasis on a traction-induced foveal pathology. A prospective study of spectral-domain optical coherence tomography.

Authors:  George P Theodossiadis; Irini P Chatziralli; Theodoros N Sergentanis; Ioannis Datseris; Panagiotis G Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-15       Impact factor: 3.117

4.  Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.

Authors:  Andrea Cacciamani; Roberto Gattegna; Marco Pileri; Marta Di Nicola; Sara Bardanzellu; Giuliana Facciolo; Pamela Cosimi; Andrea Govetto; Fabio Scarinci
Journal:  Int Ophthalmol       Date:  2019-09-29       Impact factor: 2.031

5.  [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].

Authors:  M Maier; S Abraham; C Frank; C P Lohmann; N Feucht
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

6.  The Charles Schepens Lecture: Management Options for Vitreomacular Traction: Use an Individualized Approach.

Authors:  Harry W Flynn; Nidhi Relhan
Journal:  Ophthalmol Retina       Date:  2017 Jan-Feb

Review 7.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

8.  Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes.

Authors:  Jonathan S Chang; William E Smiddy
Journal:  Ophthalmology       Date:  2014-05-15       Impact factor: 12.079

Review 9.  A review of current management of vitreomacular traction and macular hole.

Authors:  Alfredo García-Layana; José García-Arumí; José M Ruiz-Moreno; Lluís Arias-Barquet; Francisco Cabrera-López; Marta S Figueroa
Journal:  J Ophthalmol       Date:  2015-03-03       Impact factor: 1.909

10.  PROGRESSION OF PARTIAL POSTERIOR VITREOUS DETACHMENT OVER TIME.

Authors:  Elizabeth C Koller; Jessica A Kraker; Eileen S Hwang
Journal:  Retina       Date:  2021-07-01       Impact factor: 3.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.